Altimmune(US:ALT)2025-08-12 11:10Financial Performance - As of June 30, 2025, Altimmune reported cash, cash equivalents, and short-term investments totaling $183.1 million, a 39% increase from $131.9 million as of December 31, 2024[9]. - Revenues for Q2 2025 were $5,000, compared to $5,000 in Q2 2024, showing no growth year-over-year[16]. - Total operating expenses for Q2 2025 were $22,927, a decrease of 14% from $26,750 in Q2 2024[16]. - Net loss for Q2 2025 was $22,146, compared to a net loss of $24,640 in Q2 2024, indicating a 10% improvement[16]. - Net loss per share for Q2 2025 was $0.27, compared to $0.35 in Q2 2024, reflecting a decrease of 23%[16]. - Comprehensive loss for Q2 2025 was $22,182, slightly improved from $24,671 in Q2 2024[16]. - Interest income for Q2 2025 was $1,132, a decrease of 48% from $2,182 in Q2 2024[16]. - Total other income for Q2 2025 was $776, down from $2,105 in Q2 2024, marking a 63% decline[16]. - Income tax benefit for the six months ended June 30, 2025, was $681, compared to no tax expense in the same period of 2024[16]. Research and Development - In the IMPACT Phase 2b trial, statistically significant MASH resolution was observed in up to 59.1% of patients receiving pemvidutide, with fibrosis improvement in up to 34.5% of treated patients[5]. - Pemvidutide demonstrated a statistically significant weight loss of up to 6.2% at 24 weeks, with a continuing trajectory of weight loss[5]. - Mean decreases in corrected T1 (cT1) relaxation time were 145.0 ms and 147.9 ms in the pemvidutide 1.2 mg and 1.8 mg groups, respectively, compared to a decrease of 27.5 ms in the placebo group (p < 0.001 for both)[5]. - The ongoing IMPACT trial is expected to provide data on weight loss, non-invasive tests, and safety at 48 weeks in Q4 2025[5]. - An End-of-Phase 2 Meeting with the FDA is targeted for Q4 2025[5]. - The company initiated the RECLAIM Phase 2 trial for Alcohol Use Disorder (AUD) in May 2025, expected to enroll approximately 100 subjects[9]. - The RESTORE Phase 2 trial for Alcohol-Associated Liver Disease (ALD) was initiated in July 2025, also expected to enroll around 100 subjects[9]. Expense Management - Research and development expenses for the three months ended June 30, 2025, were $17.2 million, down from $21.2 million in the same period in 2024[9]. - Research and development expenses in Q2 2025 were $17,236, down from $21,155 in Q2 2024, representing an 18% reduction[16].